Treatment of osteoporosis after liver transplantation with ibandronate

Transplant International

Volumn 23, Issue 7, 2010, Pages 753-759

  Kaemmerer, Daniel ^a   Lehmann, Gabriele ^b   Wolf, Gunter ^b   Settmacher, Utz ^b   Hommann, Merten ^a  

^a Bad Berka GmbH   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Bone mineral density loss; Fractures; Liver transplantation; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; COLECALCIFEROL; CYCLOSPORIN; IBANDRONIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PREDNISOLONE; THYMOCYTE ANTIBODY; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FRACTURE; HUMAN; LIMB FRACTURE; LIVER TRANSPLANTATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE; BLOOD; DRUG EFFECTS; FRACTURES, BONE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PHOTON ABSORPTIOMETRY;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; ALKALINE PHOSPHATASE; BONE DENSITY; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE;

EID: 77953208035     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01061.x     Document Type: Article

References (47)

1. Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 2001 69 : 321.
2. Dequeker J, Borghs H, Van Cleemput J, Nevens F, Verleden G, Nijs J. Transplantation osteoporosis and corticosteroid-induced osteoporosis in autoimmune diseases: experience with alfacalcidol. Z Rheumatol 2000 59 (Suppl. 1 53.
3. Negri AL, Plantalech LC, Russo Picasso MF, Otero A, Sarli M. [Post-transplantation osteoporosis]. Medicina (B Aires) 1999 59 : 777.
4. Bjoro K, Brandsaeter B, Wiencke K, et al. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease. Scand J Gastroenterol 2003 38 : 320.
5. Figueiredo FA, Brandao C, Perez Rde M, Barbosa WF, Kondo M. Low bone mineral density in noncholestatic liver cirrhosis: prevalence, severity and prediction. Arq Gastroenterol 2003 40 : 152.
6. Trautwein C, Possienke M, Schlitt HJ, et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 2000 95 : 2343.
7. Carey E, Balan V. Metabolic bone disease in patients with liver disease. Curr Gastroenterol Rep 2003 5 : 71.
8. Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis. Endocrinol Metab Clin North Am 2007 36 : 937.
9. Hommann M, Abendroth K, Lehmann G, et al. Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation. Transplant Proc 2002 34 : 2296.
10. Sambrook PN, Kelly PJ, Keogh AM, et al. Bone loss after heart transplantation: a prospective study. J Heart Lung Transplant. 1994 13 : 116 discussion 21.
11. Compston JE. Osteoporosis after liver transplantation. Liver Transpl 2003 9 : 321.
12. Suzuki K, Takahashi J, Takada H, Kuwayama H. [Osteoporosis associated with chronic liver disease]. Nippon Rinsho. 2004 62 (Suppl. 2 728.
13. Fahrleitner A, Prenner G, Leb G, et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone 2003 32 : 96.
14. Marignani M, Angeletti S, Capurso G, Cassetta S, Delle Fave G. Bad to the bone: the effects of liver diseases on bone. Minerva Med 2004 95 : 489.
15. Schacht E. [Osteoporosis in rheumatoid arthritis - significance of alfacalcidol in prevention and therapy]. Z Rheumatol 2000 59 (Suppl. 1 10.
16. Millonig G, Graziadei IW, Eichler D, et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 2005 11 : 960.
17. Bodingbauer M, Wekerle T, Pakrah B, et al. Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation. Am J Transplant 2007 7 : 1763.
18. Reeves HL, Francis RM, Manas DM, Hudson M, Day CP. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 1998 4 : 404.
19. Crawford B, Kam C, Pavlovic J, Byth K, Handelsmann DJ, Angus PW. Summaries for patients. Zolendronic acid prevents bone loss after liver transplantation. Ann Intern Med 2006 144 : I37.
20. Pennisi P, Trombetti A, Giostra E, Mentha G, Rizzoli R, Fiore CE. Pamidronate and osteoporosis prevention in liver transplant recipients. Rheumatol Int. 2006 27 : 251.
21. Desai R, Jamieson NV, Gimson AE, et al. Quality of life up to 30 years following liver transplantation. Liver Transpl 2008 14 : 1473.
22. Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001 357 : 342.
23. Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med 1998 104 : 459.
24. Sambrook P. Corticosteroid-induced osteoporosis. Aust Fam Physician 1994 23 : 1965.
25. Chan YM, Zaitun Y, Suriah AR, et al. Efficacy of calcium supplementation and weight-bearing exercise in reducing rate of bone loss in postmenopausal Chinese women - a two-year randomized controlled trial. Asia Pac J Clin Nutr 2004 13 : S149.
26. Conley E, Muth B, Samaniego M, et al. Bisphosphonates and bone fractures in long-term kidney transplant recipients. Transplantation 2008 86 : 231.
27. Dolgos S, Hartmann A, Bonsnes S, et al. Determinants of bone mass in end-stage renal failure patients at the time of kidney transplantation. Clin Transplant 2008 22 : 462.
28. Papaioannou A, Kennedy CC, Freitag A, et al. Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). Chest 2008 134 : 794.
29. Valta H, Jalanko H, Holmberg C, Helenius I, Makitie O. Impaired bone health in adolescents after liver transplantation. Am J Transplant 2008 8 : 150.
30. Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006 12 : 1390.
31. Ninkovic M, Skingle SJ, Bearcroft PW, Bishop N, Alexander GJ, Compston JE. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 2000 12 : 931.
32. Krieg MA, Seydoux C, Sandini L, et al. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int 2001 12 : 112.
33. Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 2005 79 : 108.
34. Shane E, Rodino MA, McMahon DJ, et al. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J Heart Lung Transplant 1998 17 : 1089.
35. Dooley M, Balfour JA. Ibandronate. Drugs. 1999 57 : 101 discussion 9-10.
36. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993 91 : 2004.
37. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003 14 : 801.
38. Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ, Body JJ. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 1996 11 : 587.
39. Ringe JD, Dorst A, Faber H, Ibach K, Preuss J. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford) 2003 42 : 743.
40. Luhe A, Kunkele KP, Haiker M, et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicol In Vitro 2008 22 : 899.
41. Melton LJ III., Thamer M, Ray NF, et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997 12 : 16.
42. Cockerill W, Lunt M, Silman AJ, et al. Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 2004 15 : 113.
43. Behre A, Janott J, Pfohl M, Schatz H, Pfeiffer A. [Clinical value of urinary pyridinium crosslinks as osteoporosis markers: evaluation of a population survey of vertebral osteoporosis]. Med Klin (Munich) 2001 96 : 378.
44. Rosen HN, Moses AC, Garber J, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000 66 : 100.
45. Schmolke B. [Laboratory diagnosis of osteoporosis]. Der Orthopade 2001 30 : 425.
46. Giza D, Stompor T, Katra B, Sieradzki J, Sulowicz W. [Bone metabolism as assessed with selected markers of bone turnover as well as densitometry analysis in patients after successful kidney transplantation]. Przegl Lek 2001 58 : 979.
47. Kusec V, Smalcelj R. [Importance of biochemical indicators of bone turnover in patients on chronic dialysis and after kidney transplantation]. Acta Med Croatica 2004 58 : 51.